Leidos is trading at $116.75, down 4.06% in pre-market, with no fresh October 12 company announcement clearly explaining the decline.
- JPMorgan’s October 8 downgrade to Neutral from Overweight and price-target cut from $160 to $142 cited Health-segment margin concerns and a challenging 2027 setup; its timing does not establish it as today’s catalyst.
- Leidos announced a potential $988 million NGA contract on October 11, positive news that does not explain the drop. Major indices are modestly higher, and the provided market context does not point to a broad-market selloff as the driver.